Polygenic disease risk scoring and genetic non-discrimination

Area of Science:

• Genomics and Genetic Medicine
• Bioethics and Law
• Public Health Policy

Background:

• The Genetic Information Nondisciscrimination Act (GINA) was enacted to prevent genetic discrimination in employment and health insurance.
• Genomic medicine has advanced significantly, enabling individualized genetic risk assessments through polygenic risk scores (PGSs).
• PGSs offer potential benefits for disease prevention but also raise concerns regarding discrimination.

Purpose of the Study:

• To evaluate the adequacy of existing legal protections, such as GINA, in the context of widespread polygenic risk score (PGS) testing.
• To explore the potential benefits and concerns associated with the clinical implementation of PGSs.
• To propose new legal and policy strategies for the responsible integration of PGSs into healthcare.

Main Methods:

• Analysis of existing legal frameworks, including the Genetic Information Nondisciscrimination Act (GINA).
• Review of scientific literature on polygenic risk scores (PGSs) and their clinical applications.
• Examination of potential discrimination risks associated with PGS testing.

Main Results:

• Current legal protections may be insufficient to address the complexities and widespread use of polygenic risk scores (PGSs).
• The probabilistic nature of PGSs presents unique challenges for antidiscrimination law.
• There is a growing need for updated legal and policy approaches to support the beneficial use of PGSs in clinical practice.

Conclusions:

• Existing antidiscrimination laws require re-evaluation in light of advancements in genomic medicine, particularly polygenic risk scores (PGSs).
• New legal and policy frameworks are necessary to safeguard individuals from potential discrimination related to PGS testing.
• Proactive policy development is crucial to facilitate the responsible and beneficial clinical integration of PGSs.